malignant tumor
Conditions
Interventions
Group 1:
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. No restrictions,on gender, age or race;; 2. Patients who are diagnosed with cancer after pathological diagnosis; 3. Laboratory physical examination results or abnormal laboratory examination results with no clinical significance; 4. Comply with the principle of informed consent and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Known sensitivity to excipients in Ciprofol injectable emulsion; history of drug allergies (including other anesthetics); 2. Patient having contraindications to deep sedation/general anesthesia or a history of past sedation/anesthesia accidents; 3. History or evidence of any one of the following diseases prior to screening/enrollment: History of cardiovascular diseases; respiratory insufficiency; history of failed tracheal intubation; history of bronchospasm requiring treatment within 3 months prior to screening; history of mental illness: schizophrenia; 4. Any medication that has the potential to interact synergistically with Ciprofol, including but not limited to all sedatives and hypnotics; 5. Any condition, which in the investigator's opinion, puts the subject at significant risk, could confound the study results or may interfere significantly with the subject's participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma Ciprofol concentration;Plasma M4 concentration;Bispectrum Index, BIS ; | — |
Countries
China
Contacts
Public ContactXin Tian
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed